Literature DB >> 4044055

Expression of cell surface glycoproteins in human melanoma cell lines with different tumorigenic properties.

O Berthier-Vergnes, J Portoukalian, J F Doré.   

Abstract

Human malignant melanoma cell lines characterized by either a high or a low ability to grow subcutaneously in athymic nude mice have been examined for their cell-surface glycoproteins. Striking differences were demonstrated between these 2 groups. Cells from lines of low tumorigenicity (LT group) displayed twice as much Vibrio cholerae neuraminidase and galactose oxidase accessible glycoproteins as cells from lines of high tumorigenicity (HT group) and each group of cell lines could be characterized by specific glycoprotein profiles. LT and HT group cells displayed similar amounts of periodate accessible glycoproteins, but sialoglycoprotein profiles were characteristic for each group of cell lines. Furthermore, whereas 87% of the sialic acid released by V. cholerae neuraminidase came from cell surface glycoproteins in HT group cells, only 53-55% of the released sialic acid came from surface glycoproteins in LT group cells. These results suggest that human melanoma cell lines exhibiting different tumorigenicity in nude mice can also be characterized by differences in composition and organization within the plasma membranes of their cell-surface sialoglycoproteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044055     DOI: 10.1002/ijc.2910360408

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Tumorigenic human squamous lung cancer cells have defined cell surface carbohydrates that are absent from nontumorigenic cells.

Authors:  D E Pettijohn; O Pfenninger; J Brown; R Duke; L Olsson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas, and metastases.

Authors:  Y Matsushita; N Yamamoto; H Shirahama; S Tanaka; S Yonezawa; T Yamori; T Irimura; E Sato
Journal:  Jpn J Cancer Res       Date:  1995-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.